Kenneth Hoberman, Director at Nuvectis Pharma, Inc. (NVCT), bought 12,000 shares at $17.40 ($209K) on 2022-05-12, disclosed to the SEC on 2022-05-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.40 | 6,000 | $104K | 50.0% |
| 2 | $17.40 | 6,000 | $104K | 50.0% |
| Total | $17.40 avg | 12,000 | $209K | 100% |
| Filing → |
| STML | SELL | 2020-01-24 | $311K | — | Filing → |
| STML | SELL | 2020-01-10 | $274K | — | Filing → |
| STML | SELL | 2020-01-03 | $937K | — | Filing → |